You are here

Regeneron Announces Upcoming Investor Conference Call

TARRYTOWN, N.Y., March 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • J.P. Morgan 2019 Spring Biotech Conference Call Series at 1:00 p.m. Eastern Time on Friday, March 15, 2019

The session may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.  A replay of the webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information:
Investor Relations
Mark Hudson
914.847.3482
mark.hudson@regeneron.com 

Corporate Communications
Alexandra Bowie
914.847.3407
alexandra.bowie@regeneron.com 

 

Cision View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-call-300809394.html

SOURCE Regeneron Pharmaceuticals, Inc.